Overview
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HE
Status:
Unknown status
Unknown status
Trial end date:
2020-10-01
2020-10-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+). A new high potential trastuzumab conjugate T-DM1(trastuzumab was linked with the cytotoxic agent mertansine DM1)was tested with endocrine therapy and without against a standard arm with trastuzumab and endocrine therapy.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
West German Study GroupCollaborator:
Roche Pharma AGTreatments:
Ado-trastuzumab emtansine
Aromatase Inhibitors
Maytansine
Trastuzumab
Criteria
Inclusion Criteria:- Female patients, age at diagnosis 18 years and above (consider patients at 70 years
and above for ADAPT Elderly)
- Histologically confirmed unilateral primary invasive carcinoma of the breast
- Clinical T1 - T4 (except inflammatory breast cancer)
- All clinical N (cN)
- No clinical evidence for distant metastasis (M0)
- Known HR status and HER2 status (local pathology) Tumor block available for central
pathology review
- Performance Status ECOG ≤ 1 or KI ≥ 80%
- Negative pregnancy test (urine or serum) within 7 days prior to start of induction
treatment in premenopausal patients
- Written informed consent prior to beginning specific protocol procedures, including
expected cooperation of the patients for the treatment and follow-up, must be obtained
and documented according to the local regulatory requirements
- The patient must be accessible for treatment and follow-up
Additional Inclusion criteria for participation in the HER2+/HR+ sub-protocol:
- Confirmed ER and/or PR positive and HER2+ by central pathology
- Clinical cT1c - T4a-c (participation of patients with tumors >cT2 is strongly
recommended)
- All clinical N (participation of patients with cN0, if cT1c is strongly recommended)
- Patients must qualify for neoadjuvant treatment
- LVEF > 50%; LVEF within normal limits of each institution measured by echocardiography
and normal ECG (within 42 days prior to induction treatment)
Exclusion Criteria:
- Known hypersensitivity reaction to the compounds or incorporated substances
- Prior malignancy with a disease-free survival of < 10 years, except curatively treated
basalioma of the skin, pTis of the cervix uteri
- Non-operable breast cancer including inflammatory breast cancer
- Previous or concurrent treatment with cytotoxic agents for any reason after
consultation with the sponsor
- Concurrent treatment with other experimental drugs. Participation in another clinical
trial with any investigational not marketed drug within 30 days prior to study entry
- Male breast cancer
- Concurrent pregnancy; patients of childbearing potential must implement
- a highly effective (less than 1% failure rate) non-hormonal contraceptive measures
during the study treatment
- Breast feeding woman
- Sequential breast cancer
- Reasons indicating risk of poor compliance Patient not able to consent
Additional Exclusion Criteria for participation in the HER2+/HR+ sub-protocol:
- Known polyneuropathy ≥ grade 2
- Severe and relevant co-morbidity that would interact with the application of cytotoxic
agents or the participation in the study
- Inadequate organ function (e.g. hepatic impairment, pulmonary disease, etc.)
- Uncompensated cardiac function (current unstable ventricular arrhythmia
- requiring treatment, history of symptomatic CHF NYHA classes II-IV), history of
myocardial infarction or unstable angina pectoris within 6 months of enrollment,
history of severe hypertension, CAD - coronary artery disease)
- Severe dyspnea
- Pneumonitis
Abnormal blood values:
- Thrombocytopenia > CTCAE grade 1
- Increases in ALT/AST > CTCAE grade 1
- Hypokalaemia > CTCAE grade 1
- Neutropenia > CTCAE grade 1
- Anaemia > CTCAE grade 1